Fialuridine
From Wikipedia, the free encyclopedia
 |
|
|
Fialuridine
|
|
| Systematic (IUPAC) name | |
| 1-[(2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)- 2-tetrahydrofuranyl]-5-iodopyrimidine-2,4-dione | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C9H10FIN2O5 |
| Mol. mass | 372.09 g/mol |
| Synonyms | 2′-Fluoro-5-iodouracil |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Fialuridine, or 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU), is a nucleoside analogue . It was originally designed as a therapy for hepatitis B virus infection. Unexpected toxicity lead to the death of 5 out of 15 patients in a clinical study at the NIH from fulminant liver failure. This toxicity was unusual in that it was not predicted by animal studies.
[edit] References
- McKenzie R, Fried MW, Sallie R, et al (1995). "Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B". N. Engl. J. Med. 333 (17): 1099-105. PMID 7565947.
- Review of the Fialuridine (FIAU) Clinical Trials, Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, Division of Health Sciences Policy INSTITUTE OF MEDICINE Frederick J. Manning and Morton Swartz, Editors NATIONAL ACADEMY PRESS Washington, D.C.1995
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
